Stockscreener 앱 받기
4.56
1.22%
0.06
전일 마감가:
$4.50
열려 있는:
$4.55
하루 거래량:
157.70K
Relative Volume:
0.25
시가총액:
$481.00M
수익:
$45.44M
순이익/손실:
$-35.43M
주가수익비율:
-13.41
EPS:
-0.34
순현금흐름:
$-25.39M
1주 성능:
-1.83%
1개월 성능:
+3.76%
6개월 성능:
+4.95%
1년 성능:
-7.79%
1일 변동 폭
$4.48
$4.59
1주일 범위
$4.26
$4.90
52주 변동 폭
$3.165
$5.26
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
MXCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
4.555 | 481.00M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
132.21 | 229.43B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.47 | 154.98B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
399.63 | 152.12B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.94 | 117.84B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
72.19 | 42.52B | 6.60B | 4.16B | 490.10M | 6.93 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-29 | 개시 | Craig Hallum | Buy |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-24 | 개시 | BTIG Research | Buy |
| 2021-08-24 | 개시 | Cowen | Outperform |
| 2021-08-24 | 개시 | Stephens | Overweight |
| 2021-08-24 | 개시 | Stifel | Buy |
| 2021-08-24 | 개시 | Wedbush | Outperform |
| 2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks
MaxCyte Expands Stock Capital with New Common Stock Issuance - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by Gagnon Securities LLC - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
ConnectOne Bancorp (CNOB) Issues Press Release on Acquisition of SeQure Dx by MaxCyte - Defense World
MaxCyte, Inc. Acquires SeQure DX Inc. to Enhance Cell Engineering Offerings - Defense World
MaxCyte director exercises options, sells shares - Investing.com
MaxCyte Announces Executive Stock Transaction - TipRanks
MaxCyte director exercises options, sells shares By Investing.com - Investing.com Canada
MaxCyte Acquires SeQure Dx - FinSMEs
MaxCyte Buys SeQure Dx for Up to $7M - USA Herald
MaxCyte announces acquisition of SeQure Dx - ShareCast
Market news - Research the market
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) -January 30, 2025 at 10:37 am EST - Marketscreener.com
Cell Engineering Biz MaxCyte Buys Gene Firm For Up To $7M - Law360
MaxCyte buys gene therapy analytics firm SeQure Dx -January 30, 2025 at 08:56 am EST - Marketscreener.com
MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion - TipRanks
Cell Engineering Group MaxCyte Buys US-based SeQure Dx -January 30, 2025 at 05:05 am EST - Marketscreener.com
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx -January 30, 2025 at 04:25 am EST - Marketscreener.com
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - The Manila Times
MaxCyte Expands Cell Engineering Capabilities with Acquisition of SeQure Dx - TipRanks
MaxCyte's Strategic Move: $7M Deal Transforms Gene Therapy Safety Testing Landscape - StockTitan
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame - Yahoo Finance
Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65? - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
JPMorgan Chase & Co. Decreases Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Stock Price Down 5.8%Here's What Happened - MarketBeat
How to interpret MaxCyte Inc (MXCT)’s stock chart patterns - US Post News
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
MaxCyte Sees Increase in BlackRock Holdings - TipRanks
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why - Yahoo Finance
BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks
MaxCyte (NASDAQ: MXCT) Announces Preliminary Financial Results for Q4 and FY 2024ROCKVILLE, MD, January 13, 2025 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent cell-engineering company specializing in platform technologies for adv - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLC - Defense World
Barclays PLC Has $645,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy - MSN
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing? - Yahoo Finance
Maxcyte general counsel sells shares worth $20,271 By Investing.com - Investing.com Nigeria
MaxCyte estimates higher Q4 core revenue from last year - MSN
David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock - MarketBeat
Maxcyte general counsel sells shares worth $20,271 - Investing.com
MaxCyte expects growth in core revenue for Q4 and full year 2024 - Investing.com Canada
MaxCyte (NASDAQ:MXCT) Shares Up 8.2%Here's Why - MarketBeat
MaxCyte expects growth in core revenue for Q4 and full year 2024 By Investing.com - Investing.com South Africa
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
자본화:
|
볼륨(24시간):